Jyrki Liljeroos of Santen Oy is new Chairman of Pharma Industry Finland PIF

The Board of PIF elected Managing Director Jyrki Liljeroos of Santen Oy as the new Chairman of the Board. CEO of Santen, the pharmaceutical company focusing on ophthalmic medicines since 1997, Mr Liljeroos has a career of over 30 years with the pharmaceutical industry.

“The pharmaceutical industry is a growth sector with the potential of being one of the cornerstones of Finnish economy. It is vital that Finland's next Government concentrates on strengthening the country's business and economy without, however, forgetting people's working capacity and equal healthcare services to all", Mr Liljeroos outlines the near future.

In its meeting of 22 January, the PIF Board elected CEO Jaakko Linna of Takeda and CEO Marko Koistila of GSK as the Board Vice Chairs. Other Board members are Country Director Matti Arvela of Amgen, CEO Rainer Bitzer of Bayer, Country Director Sébastien Delarive of Sanofi, CEO Päivi Kerkola of Pfizer, CEO Vesa Loponen of Swedish Orphan Biovitrum, CEO Remi Menes of AbbVie, CEO Ilpo Tolonen of MSD,  CEO Antti Viitanen of Novartis and Country Director Jenni Vuola of Sanofi Pasteur MSD.

Further information:

Jyrki Liljeroos, Board Chairman, Pharma Industry Finland PIF, tel.  +358 400 625 770

Jussi Merikallio, General Manager, Pharma Industry Finland PIF, tel. +358 50 667 48   

26. Jan 2015